Volume 4.06 | Feb 16

Mammary Cell News 4.06 February 16, 2012
Mammary Cell News
     In this issue: Publications | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Mammary Cell News on Twitter
Enhancing the Effectiveness of a Breast Cancer Treatment
A team of researchers has identified a sequential treatment regimen that enhances the effectiveness of trastuzumab in xenotransplant models of breast cancer. [Press release from EurekAlert! discussing online prepublication in the Journal of Clinical Investigation] Press Release | Abstract

Use Aldefluor to Detect Breast Cancer Stem Cells - Click here to learn more
PUBLICATIONS (Ranked by Impact Factor of the Journal)

Global MicroRNA Level Regulation of EGFR-Driven Cell-Cycle Protein Network in Breast Cancer
Here, investigators combined a large-scale microRNA (miRNA) screening approach with a high-throughput proteomic readout and network-based data analysis to identify which miRNAs are involved in the EFGR protein network, and to uncover potential regulatory patterns. [Mol Syst Biol] Abstract

Radiation-Induced Reprogramming of Breast Cancer Cells
Using non-breast cancer stem cells (BCSCs) sorted from patient samples, researchers found that ionizing radiation reprogrammed differentiated breast cancer cells into induced BCSCs. [Stem Cells] Abstract | Press Release

CD24−/low Stem-Like Breast Cancer Marker Defines the Radiation-Resistant Cells Involved in Memorization and Transmission of Radiation-Induced Genomic Instability
Investigators searched the cancer stem cell markers associated to radiation-resistance in breast cancer cell lines and studied the role of the resistant cells in the transmission of genomic instability. [Oncogene] Abstract

A Fatty Acid-Binding Protein 7/RXRβ Pathway Enhances Survival and Proliferation in Triple-Negative Breast Cancer
In this study, researchers examine fatty acid binding protein 7 expression in a cohort of 176 primary breast cancers by gene profiling and tissue microarray immunostaining. [J Pathol] Abstract

Mediator Subunits MED1 and MED24 Cooperatively Contribute to Pubertal Mammary Gland Development and Growth of Breast Carcinoma Cells
Here, scientists provide evidence that the MED24-containing submodule of Mediator functionally communicates specifically with MED1 in pubertal mammary gland development. [Mol Cell Biol] Abstract

Protein Pathway Activation Mapping Reveals Molecular Networks Associated with Anti-Estrogen Resistance in Breast Cancer Cell Lines
Investigators postulated that changes in activation status of protein signaling networks induced by breast cancer anti-estrogen resistance genes may provide better insight into the mechanisms underlying anti-estrogen resistance. [Int J Cancer] Abstract

The Unliganded Glucocorticoid Receptor Positively Regulates the Tumor Suppressor Gene BRCA1 through GABP Beta
Here, researchers have identified a direct role for the unliganded glucocorticoid receptor in BRCA1 upregulation in the absence of hydrocortisone. [Mol Cancer Res] Abstract

Monocytes Conditioned Media Stimulate Fibronectin Expression and Spreading of Inflammatory Breast Cancer Cells in Three-Dimensional Culture: A Mechanism Mediated by IL-8 Signaling Pathway
The present study investigated the effect of media conditioned by human monocytes U937 secreted cytokines, chemokines and growth factors on the expression of adhesion molecules E-cadherin and fibronectin of human inflammatory breast cancer cell line SUM149. [Cell Commun Signal] Abstract | Press Release


First-Line Treatment of Advanced Breast Cancer with Sunitinib in Combination with Docetaxel Versus Docetaxel Alone: Results of a Prospective, Randomized Phase III Study
The purpose of this study is to investigate whether sunitinib plus docetaxel improves clinical outcomes for patients with human epidermal growth factor receptor 2/neu–negative advanced breast cancer versus docetaxel alone. [J Clin Oncol] Abstract

Predictors of Aromatase Inhibitor Discontinuation as a Result of Treatment-Emergent Symptoms in Early-Stage Breast Cancer
Women with early-stage breast cancer initiating aromatase inhibitor therapy were enrolled onto a multicenter, prospective, open-label randomized trial of exemestane versus letrozole. [J Clin Oncol] Abstract

Phase III Trial Evaluating Weekly Paclitaxel Versus Docetaxel in Combination with Capecitabine in Operable Breast Cancer
Scientists investigated whether capecitabine and docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide (FEC) or weekly paclitaxel followed by FEC would improve relapse-free survival in operable breast cancer. [J Clin Oncol] Abstract

BRCA1 Testing Should Be Offered to Individuals with Triple-Negative Breast Cancer Diagnosed Below 50 Years
Researchers have evaluated the BRCA1 mutation frequency and the implications for clinical practice of undertaking genetic testing in women with triple-negative breast cancer. [Br J Cancer] Abstract | Press Release

View Nature.com Webcast: Current Controversies - HIV Vaccines
Geron Completes Enrolment in Phase II Clinical Trial of Imetelstat in Breast Cancer
Geron Corporation announced that the company has completed enrolment in the randomized Phase II clinical trial of imetelstat, in combination with paclitaxel, in patients with locally recurrent or metastatic breast cancer. [Geron Corporation] Press Release

Foundation Funds ULM Pharmacy Professor’s Cancer Research
The Mizutani Foundation for Glycoscience, a grant-funding agency in Japan, supports the breast cancer research concept of a pharmacy professor at the University of Louisiana at Monroe (ULM). [University of Louisiana at Monroe] Press Release

Research Partnership to Improve Treatments for Cancer Patients
The Australian Cancer Research Foundation has committed $2 million towards the fit-out of two new cancer research laboratories at the Walter and Eliza Hall Institute [Walter and Eliza Hall Institute] Press Release

Pegram to Head Stanford Breast Cancer Program
Mark Pegram, MD has joined the Stanford University Medical Center to direct the breast oncology and molecular therapeutics programs. [Stanford University School of Medicine] Press Release
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW Drug Discovery World Asia
March 19-22, 2012
Singapore, Singapore

NEW 2nd EACR-OECI Joint Training Course ‘Molecular Pathology Approach to Cancer’
May 7-9, 2012
Amsterdam, Netherlands

Visit our events page to see a complete list of events in the mammary cell community.

Scientific Marketing Communications Specialist (STEMCELL Technologies Inc.)

Scientist – Pluripotent Stem Cells (STEMCELL Technologies Inc.)

Research Technologist (STEMCELL Technologies Inc.)

Scientist – hPSC (STEMCELL Technologies Inc.)

Scientist – Antibody and Hybridoma Technology Platforms (STEMCELL Technologies Inc.)

Business Analyst – Product Management (STEMSOFT Software Inc.)

Post-Doctoral Fellow, Cancer Biology (North Carolina Central University)

Postdoctoral Fellow and Technician Positions (North Carolina Central University)

Postdoctoral Research Scientist (The Beatson Institute for Cancer Research) 

Associate Professor – Breast Pathology (Tianjin Medical University Cancer Institute and Hospital) 

Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Jobs are categorized regionally: United States, Canada, Europe,
Asia Pacific

Visit here to post your career opportunities.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Mammary Cell News: Archives | Events | Contact Us

Suite 201 – 375 West Fifth Avenue
Vancouver, BC V5Y 1J6, Canada